return equiti ttm
follow zoetiss third-quart earn releas thursday morn increas
ep target ep target overal
third-quart result ahead estim compani expect
organ growth roughli basi point impress anoth
strong quarter execut includ continu strong growth compani
dermatolog portfolio manag abil navig pocket challeng
condit livestock segment longer term believ new product
allow compani consist outpac rate broader anim health spend
maintain outperform rate zoeti despit elev valuat given stabil
busi model prospect double-digit earn growth beyond
innov manag provid clariti combin flea tick
heartworm product simparica trio compani indic expect late-first-
quarter launch first-year revenu potenti million view anoth
signal manag confid receiv approv prior major buy
period parasiticid late first quarter second quarter although
compani market product commerci approv believ
veterinarian well awar offeringrecal compani present efficaci data
major veterinarian meet earli septemb survey indic willing
shift triple-combo product expect zoeti compani launch
combin product compani also provid updat
monoclon antibodi product dog cat appear launch
commerci believ eventu drug opportun
exceed million annual sale
companion anim apoquel cytopoint combin million revenu
third quarter fourth consecut quarter year-over-year growth see
exhibit total million sequenti surpris
continu signific growth million dermatolog sale
increas sequenti believ compani reach penetr
like growth rate moder move forward believ
still signific growth opportun oversea separ view phoenix lab
acquisit companion anim refer lab interest step improv abaxiss
valu proposit diagnost expect abaxi gain traction intern
compani shift direct sell model build refer lab offer
zoeti leader develop manufactur market anim health medicin vaccin
product companion anim market annual revenu exceed billion compani found
divis spun februari oper countri maintain one
largest budget industri
post-cal model adjust increas ep estim
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
exhibit quarterli apoquel cytopoint sale million present
exhibit companion vs livestock organ growth present
exhibit companion anim organ growth geographi present
livestock livestock busi expect quarter organ compar estim
flat driven somewhat lighter-than-expect perform livestock adjust revenu
outlook go organ growth expect follow flat slightli
cattl market herd expans flatten dairi farmer yet invest rel weak swine market overal
given linger impact african swine fever continu strong trend poultri high-single-digit growth
aquacultur
xxsourc compani compani report william blair compani report william blair william blair
exhibit livestock organ growth speci present
exhibit livestock organ growth geographi present
increas full-year revenu target millionth miss quarter compar modelto
billion howev follow quarter ep beat updat guidanc increas
ep target
increas revenu target million billion ep target
assum organ growth compar previous though expect headwind
foreign currenc offset increas companion segment target implicitli assum start
point million dermatolog portfolio revenu growth million increment sale
simparica trio growth rest companion anim portfolio inclus new product abaxi
remaind busi
valuat stock thought
zoeti trade time updat ep estim compar year averag time
forward earn anim health manufactur peer time ep maintain outperform rate
despit valuat premium given solid all-around result expect pipelin product extend
industry-averag revenu growth summari revis model found exhibit
view follow key risk zoeti next three five year slowdown economi neg
affect spend companion anim livestock diseas outbreak shift away usag antibiot food
anim shift away meat consumpt develop market due chang consum prefer
xxsourc compani report william blair otherxxsourc compani report william blair william blair
good gross gener research amort intang total oper oper expense/ incom pre-tax tax net loss attribut non-controlling interest- net incom excl non-recurring non-recurring item net net ep excl non-recurring per average share outstand margin analysi gross metric total revenu constant oper revenu constant incom excl non-recur excl non-recur share blair compani estimatesourc compani report william blair compani llc estim import disclosur
william blair affili market maker secur zoeti inc
william blair affili expect receiv intend seek compens invest bank servic zoeti inc affili
within next three month
offic employe william blair affili research analyst may financi interest secur zoeti
inc report avail electron form regist user via doc http //williamblairlibrari bluematrix com
pleas contact us consult williamblair com/research-and-insights/equity-research/coverag aspx disclosur
